Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Cancer Res. 2008 Nov 15;68(22):9358–9366. doi: 10.1158/0008-5472.CAN-08-1860

Fig. 1.

Fig. 1

p53R2 is a p53-dependent decitabine gene target. A, p53R2 mRNA expression in cancer cell lines following decitabine treatment. p53R2 was measured by Northern blot analysis in the indicated colorectal cancer cell lines five days post decitabine treatment, using the indicated drug concentrations. The p53 status of each cell line is indicated and the cell lines are described in the text. Ethidium bromide staining of total RNA confirmed equivalent RNA loading. B, p53R2 protein expression in cancer cell lines following decitabine treatment. p53R2 was measured by Western blot analysis under the same experimental conditions described in A. C, p53-dependent p53R2 promoter activity in decitabine-treated cells. Left: The activity of a p53R2 luciferase reporter construct containing the intron 1 p53 binding site was determined before and after decitabine-treatment in RKO (p53 wildtype) and HT29 (p53 mutant) cells. Right: activity of the p53R2 intron 1 construct containing a mutated p53 binding site.